Matritech (AMEX:MZT)
Historical Stock Chart
From Jun 2019 to Jun 2024
Matritech (AMEX:MZT) announced today that it will release its second
quarter 2007 earnings results before market opening on July 31, 2007.
The company has scheduled a conference call at 8:30 a.m. (ET) that day
to discuss the results and provide a company update. The call will be
webcast and can be accessed on the Matritech web site at www.matritech.com.
Conference Call Dial-in Number
To access the conference call by phone, the dial-in number in the United
States is 800-591-6945. The International number is 617-614-4911.
The participant pass code is 18241894. The webcast will also be
distributed over CCBN's Investor Distribution Network to both
institutional and individual investors.
About Matritech
Matritech is using its patented proteomics technology to develop
diagnostics for the detection of a variety of cancers. The Company's
first two products, the NMP22®
Test Kit and NMP22®
BladderChek® Test,
have been FDA approved for the monitoring and diagnosis of bladder
cancer. The NMP22 BladderChek Test is based on Matritech's proprietary
nuclear matrix protein (NMP) technology, which correlates levels of NMPs
in body fluids to the presence of cancer. Beginning with a patent
portfolio licensed exclusively from the Massachusetts Institute of
Technology (MIT), Matritech’s patent portfolio
has grown to 14 other U.S. patents. In addition to the NMP22 protein
marker utilized in the NMP22 Test Kit and NMP22 BladderChek Test, the
Company has discovered other proteins associated with cervical, breast,
prostate, and colon cancer. The Company’s goal
is to utilize protein markers to develop, through its own research staff
and through strategic alliances, clinical applications to detect cancer.
More information about Matritech is available at www.matritech.com.
Statement under the Private Securities Litigation Reform Act
Any forward-looking statements in this press release including those
related to the Company's expectations regarding future sales of the
Company’s products, sales in specific target
markets, future products under development by the Company or third
parties, and business prospects are subject to a number of risks and
uncertainties, many of which are beyond the Company’s
control. Please refer to the risk factors detailed in the Company’s
periodic reports and registration statements as filed with the
Securities and Exchange Commission. These forward-looking statements are
neither promises nor guarantees. There can be no assurance that the
Company’s expectations for its products or
future financial performance will be achieved. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. Matritech undertakes no responsibility to
revise or update any such forward-looking information.